Germ line mutations in the LKB1 tumor suppressor gene are associated with the Peutz-Jeghers polyposis and cancer syndrome. Somatic mutations in Lkb1 are observed in sporadic pulmonary, pancreatic and biliary cancers and melanomas. The LKB1 serine-threonine kinase functionally and biochemically links control of cellular structure and energy utilization through activation of the AMPK family of kinases. Lkb1 regulates cell polarity through downstream kinases including AMPKs, MARKs and BRSKs, and nutrient utilization and cellular metabolism through the AMPK-mTOR pathway. LKB1 has been shown to affect normal chromosomal segregation, TGF-b signaling in the mesenchyme and WNT and p53 activity. Although each of the LKB1-dependent processes and downstream pathways have been individually delineated through work across a range of experimental systems, how they relate to Lkb1's role as a tumor suppressor remains to be fully explored and elucidated. The recent development of mouse cancer models harboring engineered mutations in Lkb1 have offered insights into how LKB1 may be functioning to restrain tumorigenesis and how its role as a master regulator of polarity and metabolism could contribute to its tumor suppressor function.
Introduction
The LKB1/STK11 (Liver kinase B1/serine-threonine kinase 11) tumor suppressor encodes a ubiquitously expressed and evolutionarily conserved serine-threonine kinase. Together with the pseudokinase, STE20-related adaptor protein (STRAD), and the scaffolding protein, mouse protein 25 (MO25), LKB1 positively regulates the activity of at least 14 downstream kinases-related to the AMP-activated protein kinase (AMPK)-that are involved in the regulation of cellular responses to energy stress and the establishment of cell polarity (Baas et al., 2004b; Alessi et al., 2006; Katajisto et al., 2007) . LKB1 can also phosphorylate other substrates including STRAD and phosphatase and tensin homolog (PTEN), although the biological significance of these modifications has not been established. LKB1 was first identified as a tumor suppressor gene through its association with the Peutz-Jeghers Syndrome (PJS), a rare autosomal dominant syndrome (prevalence of PJS has been estimated at 1/50 000 (Dunlop, 2002) ) characterized by benign gastrointestinal polyps (hamartomas), and an increased risk of malignancy (Giardiello and Trimbath, 2006) . Comparative genomic hybridization and linkage analysis identified a probable PJS locus on 19p (Hemminki et al., 1997) . Subsequently, germ line truncating LKB1 mutations were found within PJS kindreds . Despite the extensive characterization of its biochemical properties, iteration of downstream pathways and evaluation in a number of biological systems, the LKB1 tumor suppressor activity has yet to be conclusively ascribed to one of-or combinations of-its established functions. LKB1 has been the focus of a number of excellent reviews (Baas et al., 2004b; Alessi et al., 2006; Forcet and Billaud, 2007; Katajisto et al., 2007; Williams and Brenman, 2008) . Below we discuss the relationships between LKB1 and cancer. We focus in particular on human genetic data in sporadic cancers, linkage of key downstream pathways to possible tumor suppressor functions emphasizing polarity control, and recent studies in engineered cancer models. We aim to place LKB1 in the context of other tumor suppressor genes and point towards possible links between this protein's ability to regulate cellular architecture and its tumor suppressor function.
Peutz-Jeghers syndrome and human cancer genetics
PJS is characterized by; (1) muco-cutaneous hyperpigmentation involving the lips and hands, (2) the early development of hamartomas, which are well-differentiated vascular polyps found throughout the gastrointestinal tract beginning at an early age and (3) an increased incidence of carcinomas (Peutz, 1921; Jeghers et al., 1949; Westerman et al., 1999) . Inactivating mutations, exonic deletions and whole gene deletions in Lkb1 are found in most PJS syndrome kindreds, with variance in the specific rate dependent on the population studied and the method used to identify mutations (Olschwang et al., 2001; Aretz et al., 2005; Volikos et al., 2006) . Although the failure to detect LKB1 mutations has led to the suggestion that other PJS genes exist, the discovery of deletions involving larger regions-that could have escaped detection using earlier techniquestemper this possibility (Aretz et al., 2005; Volikos et al., 2006) .
Hamartomatous polyps associated with PJS are remarkable for their normal cellular morphology and grade-exhibiting none of the characteristic dysplastic changes of pre-cancerous adenomatous polyps of the gastrointestinal tract. Rather, hamartomas exhibit a distorted architecture with an overgrowth of smooth muscle. Although there is a possibility that these could transform to become carcinomas, there are several lines of evidence suggesting otherwise and that this aspect of PJS might be functionally separate from the role of LKB1 in suppressing malignant transformation (see below; 'Benign and malignant tumorigenesis'). A markedly increased incidence of carcinomas of the gastrointestinal tract including stomach, small bowel, colon and pancreatic cancer, as well as breast, ovary, uterus, cervix, lung and testis cancer has been observed through longitudinal studies of affected kindreds (Giardiello et al., 1987 (Giardiello et al., , 2000 Spigelman et al., 1989; Gruber et al., 1998; Lim et al., 2004; Hearle et al., 2006) . In addition, rare tumors have been associated with PJS including those of a reproductive origin-including testicular and ovarian sex cord tumors, Sertoli cell tumors and adenoma malignum of the cervix-as well as non-adenocarcinoma pancreatic tumors, including pancreatic intraductal papillary mucinous neoplasia and serous cystadenomas (Podczaski et al., 1991; Young et al., 1995; Tomlinson and Houlston, 1997; Su et al., 1999; Sato et al., 2001; Yee et al., 2003) .
LKB1 is also an established suppressor of sporadic cancer. Mutational analysis across a range of sporadic tumors has identified loss of function LKB1 mutations most frequently in non-small cell lung carcinomas; between 5 and 17% of cases depending on the population studied (Sanchez-Cespedes et al., 2002; Ji et al., 2007; Koivunen et al., 2008) . Somatic inactivating mutations in LKB1 have also been reported in approximately 5% of pancreatic cancers and melanomas, and in single specimens of prostate cancer and cervical cancer (Avizienyte et al., , 1999 Bignell et al., 1998; Wang et al., 1998; Guldberg et al., 1999; Rowan et al., 1999; Su et al., 1999; Forster et al., 2000; Ikediobi et al., 2006) . Overall, the incidence of LKB1 mutation in sporadic cancers, other than lung cancer, appears low despite the high penetrance of carcinomas associated with PJS. It should be noted that hemizygous loss of chromosome 19p, spanning the LKB1 locus, is observed in many cancer types. This single-copy inactivation of LKB1, together with data from mouse models, may indicate that LKB1 can behave as a haploinsufficient tumor suppressor (see below; 'Benign and malignant tumorigenesis'). In addition, some data suggest that LKB1 can be inactivated epigenetically in sporadic cancers. LKB1 promoter hypermethylation has been reported in nearly 50% of sporadic papillary breast cancers and 12% of testicular cancers, whereas LKB1 promoter hypermethylation appears uncommon or absent in other types of sporadic breast cancers, as well as colon, gastric and pancreatic cancers (Esteller et al., 2000) . In addition, loss of LKB1 expression has been noted in sporadic endometrial cancers (Contreras et al., 2008) , neuroendocrine lung cancers and pancreatic cancers (Sahin et al., 2003; Amin et al., 2008) .
Protein structure and localization LKB1 encodes a 433 amino acid (436 in the mouse) ubiquitously expressed protein with N-and C-terminal regulatory domains as well as a central catalytic domain (residues 49-309). There is a single homolog of LKB1 in the human genome and single orthologs exist for mouse (Lkb1), Caenorabhditis elegans (PARtitioning of cytoplasm family member-4; par-4), Drosophila and Xenopus (Xenopus egg and embryo kinase 1; Xeek1). In mammalian cells LKB1 forms a complex with STRAD (a pseudokinase that shares homology with the STE20 family of kinases) and MO25, both of which are required for enzymatic activity (Hawley et al., 2003; Boudeau et al., 2004) . When overexpressed alone, LKB1 is localized primarily in the nucleus, however, when expressed with STRAD and MO25, it is found largely in the cytosol (Tiainen et al., 2002; Baas et al., 2003) . Immunohistochemical studies show that endogenous levels of LKB1 are predominantly cytoplasmic in the pancreas and liver in vivo (Hezel AF and Bardeesy N, unpublished data) . When complexed with STRAD and MO25, LKB1 shows constitutive activation in vitro (that is, for LKB1 to be catalytically active, it does not require phosphorylation by an upstream kinase). STRAD interaction and cytosolic localization appear to be required for the capacity of LKB1 to induce G1 growth arrest in an LKB1-deficient cancer cell line (G361 melanoma cells) as an LKB1 point mutation identified in a PJS kindred that abrogates this interaction, but does not compromise kinase activity, fails to promote G1 arrest (Baas et al., 2003) .
The N-terminal domain contains a nuclear localization signal and at least one phosphorylation site (S31) (Sapkota et al. 2002a) , whereas the C-terminal domain harbors three known phosphorylation sites (S325, T366 and S428), the latter two of which are targeted by ATM (ataxia telangiectasia mutated), and protein kinase A (PKA), ribosomal protein S6 kinase 90 kDa or protein kinase C z, respectively (Collins et al., 2000; Xie et al., 2006; Sapkota et al. 2002a, b) . LKB1 also has a number of autophosphorylation sites (T185, T189, T336 and S404). In addition LKB1 also has a carboxyterminal prenylation motif and is farnesylated in cells. Mutation of these sites does not affect LKB1 kinase activity or subcellular localization under basal conditions, whereas mutants at S428 do not show appropriate cytoplasmic translocation under oxidative stress (Song et al., 2007) . In addition, mutation of T336 or S428 abrogates the capacity for LKB1 to induce G1 arrest in G361 cells (Sapkota et al., 2001; Sapkota et al. 2002a, b) .
Inactivating homozygous mutation of Lkb1 in mice is embryonically lethal with mice dying midgestation, demonstrating neural tube defects and vascular abnormalities (Ylikorkala et al., 2001) . Heterozygous mice are viable but develop hamartomatous polyps, characteristic of PJS, with high penetrance (Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002) .
Biochemical functions of LKB1
Regulation of AMPK and related kinases LKB1 has been termed a master kinase based on its ability to control the activity of the 14 members of the AMPK-related family of serine-threonine kinases through direct phosphorylation of a threonine residue in their activation loops (see Figures 1 and 2 ) (Lizcano et al., 2004) . Cells lacking LKB1 have decreased activity of these AMPK family kinases whereas restoration of wild-type LKB1 rescues their catalytic activity. AMPK, the best studied among these, is central to the maintenance of cellular energy homeostasis, coordinating catabolic and anabolic cellular activities in normal and transformed cells (Carling, 2004; Shaw, 2006; Hardie, 2007) . AMPK is composed of a catalytic (a) subunit and two regulatory (b and g) subunits. In response to an increase in the AMP/ATP ratio, AMP binds to the regulatory AMPKg subunit, resulting in a conformation shift that is thought to prevent dephosphorylation of a critical threonine residue in the activation loop of AMPKa (Hardie, 2007) . LKB1 is the major upstream kinase that phosphorylates and activates AMPK (Shaw et al., 2004b) ; activated AMPK phosphorylates a number of proteins resulting in a decrease in ATP-consuming processes and an increase in ATP production through inhibition of protein synthesis, fatty acid and glucose metabolism and enhancement of glucose transport (Hardie, 2007) . AMPK turns off mTOR (mammalian target of rapamycin) by signaling to the tuberous sclerosis (TSC2/TSC1) tumor suppressor complex, as well by directly phosphorylating the mTOR-binding partner, raptor (regulatory associated protein of mTOR) (Corradetti et al., 2004; Shaw et al., 2004a; Gwinn et al., 2008) . TSC2/TSC1, in response, inactivates the small GTPase Rheb (Ras homology enriched in brain), which positively signals to mTOR. In some cell types, protein kinase C z contributes LKB1-AMPK signaling, possibly by phosphorylating LKB1 and promoting its cytoplasmic translocation and interaction with AMPK (Xie et al., 2006; Song et al., 2008) .
Importantly, this role of LKB1 in energy metabolism has been demonstrated in vivo in the mouse and C. elegans. Somatic deletion of Lkb1 in the mouse skeletal muscle produces defects in glucose uptake and loss of AMPK activation (Sakamoto et al., 2005; Koh et al., 2006) . Liver-specific Lkb1 deletion also causes metabolic defects and loss of activity of AMPK and increased mTOR signaling (Shaw et al., 2005) . C. elegans LKB1/Par-4 and AMPK/aak-2 are required for lifespan extension under conditions of energy stress (Narbonne and Roy, 2006) . More recently AMPK has been shown to be critical for cellular polarity and tight junction assembly (see below 'Polarity; AMPK-dependent mechanisms and links to energy stress').
Other AMPK-related kinases that are targets of LKB1 include the MARK (microtube affinity-regulating kinases that also regulate cell polarity (see below in following section). Additional AMPK-related kinases include the salt-inducible kinase 2 that regulates the cAMP response element-binding protein pathway and the less characterized NUAK1 and 2, QSK and SNRK, which appear to have functions in metabolism and stress responses (Screaton et al., 2004; Alessi et al., 2006) .
Polarity control
LKB1 is established as an evolutionarily conserved regulator of cellular polarity across a number of experimental models systems and cell types (see Figure 2 ). The first clue that LKB1 was involved in polarity regulation came from the observation that its C. elegans ortholog, par-4, is required for the asymmetric divisions that lead to formation of the anterior-posterior (A-P) axis of the early embryo (Kemphues et al., 1988; Watts et al., 2000) . Drosophila Lkb1 was then identified in a screen for mutations that affect A-P axis specification where Lkb1 mutants were found to lose posterior localization of maternal mRNAs, and show defects in the polarization of the microtubule cytoskeleton (Martin and St Johnston, 2003) . The ability of LKB1 to regulate cell polarity is conserved in cultured mammalian cells as well as in neurons and in the pancreatic epithelium. STRADmediated LKB1 translocation from the nucleus to the cytoplasm can induce three major features of cell polarity in unpolarized single epithelial intestinal cells:
(1) remodeling of the actin cytoskeleton to an apical brush border, (2) relocalization of zona occludens 1 and p120-catenin to form junctional complexes and (3) the sorting of surface proteins to apical and basolateral domains (Baas et al., 2004a) . LKB1 can also regulate the polarization of lung cancer cell lines in association with recruitment of the small GTPase, Cdc42, a known regulator of cell polarity see Etienne-Manneville, 2008) . Conditional knockout and in vivo RNAi approaches have shown that Lkb1 controls axon specification in a manner that requires the AMPK-related SAD-A and SAD-B kinases (Barnes et al., 2007; Shelly et al., 2007) . RNAi studies also showed that LKB1 is required for neuronal migration and centrosome positioning (Asada et al., 2007) . Similarly, mice with pancreas-specific Lkb1 deletion show defects in acinar cell polarity reflected by loss of tight junctions and disorganization of the cytoskeleton; virtually all AMPK-related kinases are deregulated in this system .
Polarity; AMPK-dependent mechanisms and links to energy stress Recent work has provided a fascinating and unexpected link between LKB1-and AMPK-mediated control of energy metabolism and the control of cell polarity. In MDCK epithelial cells, AMPK is activated during tight junction assembly induced by calcium withdrawal and re-addition. Moreover, disruption of AMPK function using a dominant-negative mutant delays tight junction assembly, whereas activation of AMPK with the AMP mimetic, AICAR, accelerates tight junction formation Lee et al., 2007; Zheng and Cantley, 2007) . Significantly, the effects of dominant-negative AMPK can be attenuated by addition of the mTOR inhibitor, Rapamycin, indicating that the AMPK Figure 2 LKB1 and cellular structure. The role of LKB1 in regulating aspects of cellular polarity and structure have been explored across many systems. Biologic systems (listed on the left), mechanisms (at center) and effects (to the right) in which LKB1 has been shown to have a function in cell structure are shown.
LKB1; linking cell structure and tumor suppression AF Hezel and N Bardeesy mediates its effects on tight junction assembly, in part, through inactivation of mTOR . These processes are LKB1-dependent as expression of dominant-negative LKB1 attenuates AMPK activation following the calcium switch. This function of LKB1-AMPK signaling mediating cell polarity is also seen in Drosophila (Lee et al., 2007; Mirouse et al., 2007) . The embryonic epithelium of AMPK mutants loses its normal architecture and has defective localization of polarity markers, including loss of apical localization of Bazooka and b-catenin and loss of basolateral Discs-large. These AMPK mutants also have mitotic defects resulting in polyploidy. Notably, similar phenotypes are observed in Lkb1 mutants and expression of a constitutively active AMPK mutant (catalytically active without phosphorylation by Lkb1) rescues the Lkb1 mutant phenotype. Hence, an Lkb1-AMPK pathway is critical for epithelial polarity and genomic stability in Drosophila.
Direct links between energy stress and Lkb1-AMPKregulated cell polarity were revealed by observation of Lkb1 or AMPK mutant follicular epithelial cells-the cells that surround the oocyte (Lee et al., 2007; Mirouse et al., 2007) . In a nutrient rich environment, Lkb1 or AMPK mutant cells exhibited normal architecture. However, when available sugars were reduced in the culture medium, mutants exhibited disruption of apicalbasal polarity of the actin cytoskeleton in association with mis-localization of apical, lateral and basal markers. Under these energy stress conditions, the Lkb1 mutant clones were noted to form tumor-like aggregates of unpolarized cells. These results, showing that the LKB1-AMPK pathway is critical for maintenance of cellular orientation in times of energy stress, were mirrored in a human colon cancer line where addition of 2-deoxyglucose induced cellular polarization in a manner that requires functional AMPK, but not MARK2/Par1 (Lee et al., 2007) . Collectively, these data support the view that energy sensing and cell polarity may be broadly integrated under the control of LKB1-AMPK signaling.
Mechanisms of polarity control
The mechanisms by which LKB1 contributes to polarity control are beginning to be elucidated. Kinase-dead mutants of LKB1 are incapable of inducing polarity in Drosophila and in mammalian intestinal epithelial cells indicating that LKB1 catalytic function is required (Forcet et al., 2005) . In addition, mammalian cells require STRAD-mediated translocation of LKB1 from the nucleus to the cytoplasm (Baas et al., 2004a) . Beyond these general features, it is likely the LKB1 controls cell polarity in a cell type-specific manner with different contributions from individual AMPK family members. Polarization of Drosophila oocytes and follicular epithelial cells, as well as mammalian neurons, requires the C-terminal protein kinase A site (Ser535 in Drosophila, Ser431 in mice) (Martin and St Johnston, 2003; Shelly et al., 2007) . Shelly et al., (2007) identified that the brain-derived neurotrophic factor is an upstream activator of Lkb1 that induces PKA-mediated phosphorylation of this site, providing a link between extracellular signals and Lkb1-mediated axon specification. The biochemical roles of this residue and of its phosphorylation remain to be determined. This PKA/ RSK site is also required for LKB1-mediated growth inhibition in the LKB1-deficient G361 melanoma cell line but is dispensable for LKB1-mediated regulation of polarity in migrating astrocytes (Sapkota et al., 2001; Forcet et al., 2005) . Finally, the farnesylation motif at the carboxy terminus of LKB1 is required for A-P polarity in Drosophila (Martin and St Johnston, 2003) .
In terms of downstream targets, myosin regulatory light chain (MRLC or MLC2), the regulatory subunit of Myosin II, appears to be a critical mediator of AMPKmediated changes in structure in some cell types (Lee et al., 2007) . In Drosophila, MRLC mutants show similar defects to AMPK mutants, and MRLC appears to be a direct target of AMPK phosphorylation at a site that activates the MRLC polarity function (Ser19). Significantly, expression of a phosphomimetic mutant MRLC transgene rescues the AMPK mutant phenotype consistent with the importance of an LKB1-AMPK-MRLC pathway in polarity control. Human colon cancer epithelial cells that can be polarized by LKB1 activation also become polarized under conditions of energy stress in an AMPK-and MRLC-dependent manner. In contrast to this observed AMPK-MRLC pathway, deletion of Lkb1 in the pancreatic epithelium does not lead to a decrease in p-MRLC (Ser19) . Moreover, the MRLC pathway is inhibited rather than activated by AMPK in vascular smooth muscle cells (Horman et al., 2008) .
Other members of the AMPK-related kinase subfamily regulated by LKB1 and linked to cellular polarity control include the microtubule affinity-regulating kinases (MARK1, 2, 3 and 4). The MARKs promote epithelial polarization through regulation of tubulin dynamics (Hatakeyama, 2008) . This is mediated through phosphorylation of microtubule-associated proteins, including tau, and involves alteration in cell contacts and in E-cadherin localization (Drewes et al., 1997; Cohen et al., 2004 Cohen et al., , 2007 Elbert et al., 2006) . Notably, germ line deletion of MARK2 in the mouse uncovered a role in energy metabolism as MARK-deficient animals are growth retarded, have decreased adiposity and are hyperphagic (Hurov and Piwnica-Worms, 2007; . Therefore, multiple AMPK family members are likely to affect both polarity control and cell metabolism. LKB1 may also control cell polarity through additional pathways as physical interactions have been reported between LKB1 and the activator of G-protein signaling 3 (AGS3) whose Drosophila ortholog, Pins, is a key regulator of cell polarity and asymmetric division (Blumer et al., 2003) . The functional significance of this interaction has yet to be demonstrated.
How might the role of LKB1 in cell polarity relate to its tumor suppressor function? One study-using mammary epithelial cells grown in a 3-dimensional Matrigel culture system-has shown that polarity defects accompanying LKB1 inactivation unmask the oncogenic activity of c-Myc (Partanen et al., 2007) . In this system, proliferating cells eventually form into quiescent polarized acinar structures. LKB1 inactivation results in defective polarization of acini. Combined LKB1 inactivation and c-Myc induction resulted in aberrant cell-cycle progression of quiescent acinar cells that exhibited severe structural defects. These results are consistent with the notion that polarity serves to restrain cell proliferation induced by mitogenic stimuli. Another attractive possibility is that the polarity defects accompanying LKB1 inactivation could contribute to tumorigenesis by impairing genomic stability as has been shown in Drosophila (Bonaccorsi et al., 2007; Lee et al., 2007) . Large-scale RNAi screens in Drosophila cell lines suggest that Lkb1 and AMPK are required for normal cellular division (Bettencourt-Dias et al., 2004) . It will be of significant interest to determine whether chromosomal aberrations are associated with LKB1 deficiency in mammalian cells. In this regard, it is notable that mammalian neurons require LKB1 for spatial positioning of the centrosome (Asada et al., 2007) .
Other pathways in cellular growth and proliferation LKB1 has been shown to regulate a number of other pathways that could modulate cellular growth. In primary cells, AMPK can induce a G1 arrest in response to low nutrient levels dependent on activation of p53 through phosphorylation of serine-15 (Jones et al., 2005) . Notably, LKB1 introduction into the LKB1 mutant G361 melanoma cell line also promotes G1 arrest through p53 stabilization and p21 CIP1 induction (Tiainen et al., 1999 (Tiainen et al., , 2002 . The role of AMPK in the growth arrest in this system has not been investigated. LKB1 overexpression induces growth arrest independently of both p53 and AMPK in squamous cell carcinoma cells . LKB1-AMPK signaling has also been implicated in p27 KIP1 stabilization under energy stress conditions (Liang et al., 2007) . Stabilized p27 KIP1 can promote autophagy and consequent survival of cancer cells. Some studies have suggested that Lkb1 regulates PTEN signaling either through direct protein binding and phosphorylation, or through upregulation of PTEN transcription (Jimenez et al., 2003; Mehenni et al., 2005; Song et al., 2007) . In human umbilical vein endothelial cells, the presence of LKB1 downregulates AKT (S473) phosphorylation under oxidative stress, consistent with an LKB1-PTEN-AKT pathway (Song et al., 2007) . However, in other cell types, levels of downstream AKT signaling do not appear to be regulated by LKB1 (Corradetti et al., 2004; Shaw et al., 2004a) . Wnt/b-catenin signaling is also modulated by Lkb1 (Ossipova et al., 2003; Spicer et al., 2003; Lin-Marq et al., 2005) . One report suggested that Lkb1 acts at a level upstream of GSK3 to upregulate b-catenin activity (Ossipova et al., 2003) .
Knockdown of expression of the Xenopus LKB1 ortholog, XEEK1, produced phenotypes similar to those observed in loss of function mutants in the WNT pathway suggesting that these factors regulate a common pathway. In contrast, other studies have indicated that Lkb1 downregulates the b-catenin pathway through either activation of GSK3-a negative regulator of b-catenin-or through diverting MARK2/ Par1a from its capacity to activate the pathway (Spicer et al., 2003; Lin-Marq et al., 2005) . Although these observations are intriguing, the direct functional role of LKB1 in WNT signaling in vivo remains to be established.
Benign and malignant tumorigenesis
Genetically engineered mouse models and data from human specimens have begun to provide insight into the mechanisms underlying LKB1 tumor suppressor activity. It is important to note, as mentioned above, that the suppression of benign polyps (hamartomas) and of malignant tumors may be independent and functionally distinct processes. Firstly, most data suggest that hamartomas do not undergo malignant transformation and give rise to carcinomas. Jansen et al. (2006) provide a complete discussion on this point as well as an explanation for the occasional findings of carcinomatous changes within haramartomatous polyps. Furthermore, hamartomas display variable LOH of LKB1 as opposed to carcinomas in PJS patients where LOH is more frequently observed (Wang et al., 1999; Miyaki et al., 2000; Entius et al., 2001; Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002; De Leng et al., 2003) . Most intriguingly, studies in genetically engineered mouse models have called into question whether the hamartomas arise because of cell autonomous processes (a cell autonomous process involves only genotypically mutant cells exhibiting a mutant phenotype; a non-cell autonomous process involves a genotypically mutant cell causing a mutant phenotype in another cell).
Genetically engineered mice with germ line heterozygous Lkb1 inactivation develop PJS-type polyps with 100% penetrance, confirming Lkb1 as a tumor suppressor gene. The cyclooxygenase-2 pathway is deregulated in PJS hamartomas and pharmacological inhibition of cyclooxygenase-2 signaling decreases polyp growth in both Lkb1 þ /À mice and PJS patients (Rossi et al., 2002; Udd et al., 2004) . However, it has not been established whether Lkb1 directly regulates cyclooxygenase-2 or whether the upregulation of this pathway reflects other molecular alterations associated with tumor progression. Consistent with a role of LKB1 in controlling AMPK-TSC signaling, the epithelium of the polyps exhibits upregulation of the mTOR pathway (Shaw et al., 2004a) . Furthermore, treatment of Lkb1 þ /À mice with rapamycin markedly reduces the extent of polyposis in these mice suggesting that aberrant mTOR activity because of epithelial Lkb1 deficiency contributes LKB1; linking cell structure and tumor suppression AF Hezel and N Bardeesy to tumor formation (Wei et al., 2008) . In opposition to this notion, it has been shown that mice with heterozygous or homozygous deletion of Lkb1 specifically in the smooth muscle cells (including the intestinal smooth muscle; Lkb1 lox/ þ SM22Cre and Lkb1 lox/lox SM22Cre mice) develop hamartomatous polyposis that exactly recapitulate the histopathology of those seen in Lkb1 þ /À mice (Katajisto et al., 2008) . Although the polyp epithelium of Lkb1 lox Sm22-Cre mice retains wild-type Lkb1 expression, it exhibits comparable levels of mTOR pathway activation to that from polyps arising in Lkb1 þ /À mice. This argues that the mTOR deregulation seen in PJS polyps is not a cell autonomous function of Lkb1 deficiency. Notably, the authors found that the polyp epithelium of Lkb1 þ /À and Lkb1 lox Sm22-Cre mice showed deficient activation of the transforming growth factor-b (TGFb) pathway. As stromal TGFb signals are important for gastrointestinal tumor suppression, these results indicate that defective stromal TGFb production because of LKB1 deficiency could contribute to tumor formation in the epithelium (Bhowmick et al., 2004; Kim et al., 2006) . Although these data indicating a 'landscaper' function for stromal LKB1 are very compelling, the final resolution of the relative roles of LKB1 signaling in the gastrointestinal stroma and epithelium will await generation of mice with specific deletion in the latter compartment. It will be of particular interest to investigate a possible role of LKB1 in intestinal epithelial polarity, given the possibility that defects in cell polarity could compromise asymmetric divisions of intestinal stem cells and therefore lead to defects in differentiation thereby leading to polyposis.
Malignant tumors and cystic neoplasms
Loss of LKB1 in the epithelium promotes cancer In contrast to the hamartomas, the malignant tumors and some benign cystic tumors associated with LKB1 deficiency clearly reflect an epithelial, cell autonomous function of LKB1 (see Table 1 ). On certain genetic backgrounds, Lkb1 þ /À mice develop liver cancers that exhibit Lkb1 LOH . In addition, Lkb1 þ /À mice exposed to carcinogens develop malignant squamous cell carcinomas that lose expression of Lkb1 either through LOH or by transcriptional silencing of the Lkb1 locus. Significantly, mice with homozygous deletion of Lkb1 in the epidermis develop squamous cell carcinoma in the absence of carcinogens .
A number of mouse models have been established for cancers that in humans show LKB1 inactivation. LKB1 is frequently inactivated in non-small cell lung carcinomas, a tumor type that commonly harbors mutation of the K-RAS oncogene (Sanchez-Cespedes et al., 2002) . To investigate possible cooperation between oncogenic K-RAS and Lkb1 deficiency, adenovirus delivering Cre recombinase (adeno-Cre) was administered to the lungs of mice with conditional Lkb1 and activatable K-RAS G12D alleles . Lkb1 inactivation alone did not induce lung cancer, but in cooperation with K-RAS G12D , markedly accelerated tumorigenesis, promoted metastasis and lead to a distinct histological spectrum of resulting cancers. These results suggest a role for Lkb1 in regulating cell differentiation, perhaps by involving self-renewal of lung stem cell populations. Endometrial carcinoma, a tumor type associated with PJS, is observed in a subset of Lkb1 heterozygous mice (Contreras et al., 2008) . These tumors also develop following deletion of Lkb1 in the endometrium through viral delivery of Cre recombinase. Benign pancreatic tumors, known as cystadenomas, have been reported in PJS patients and in Lkb1 þ /À mice . This phenotype is recapitulated in mice with specific Lkb1 deletion in the pancreatic epithelium. Finally, based on the analysis of a limited number of cell lines, it appears that Lkb1 mutations are associated with human prostate cancer (Ikediobi et al., 2006) . In the mouse, deletion of Lkb1 in the prostatic epithelium leads to hyperplasia and prostatic intra-epithelial neoplasia (Pearson et al., 2008) .
In most of the models described above, homozygous loss of Lkb1 in the epithelium appears to be a driving force in tumorigenic progression. As the deletion of Lkb1 is targeted to the epithelium in these experiments through the use of directed Cre strains, or is confined to a small number of cells in the adeno-Cre experiments, these models are in support of a cell autonomous tumor suppression function for Lkb1. It is also possible that epithelial haploinsufficiency of Lkb1 contributes to tumorigenesis. In the K-RAS G12D adeno-Cre lung cancer model, heterozygosity for the conditional Lkb1 allele Table 1 Benign and malignant neoplasia which have been modeled in genetically engineered Lkb1 mutant mice
Lkb1 mutant models of neoplasia
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+/À Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002 [SM22-CreERT2; Lkb1 .
Genetic interaction between LKB1 and other tumor suppressor genes Crosses of Lkb1 mutants with other mouse knockout tumor suppressor strains have pointed towards synergy between Lkb1 inactivation and lesions in the PTEN and p53 pathways in tumor promotion. p53 deficiency accelerated polyposis in Lkb1 þ /À p53 þ /À mice, and resulted in shorter latency and altered the spectrum of carcinomas, suggesting that these genes control separate tumor suppressor pathways (Wei et al., 2005; Takeda et al., 2006) . Compound mutant mice with hypomorphic Lkb1 alleles-that express o20% of wild-type Lkb1 levels-and PTEN heterozygosity exhibited a comparable spectrum of tumors to PTEN þ /À mice, but showed significantly accelerated tumor progression (Huang et al., 2008) .
Mechanisms of neoplastic suppression
These different mouse models provide a number of insights into potential tumor suppressor mechanisms of LKB1, suggesting varying contributions of polarity control, AMPK activity, mTOR repression and other LKB1 targets. In some models, loss of polarity appears to be central to tumorigenesis accompanying Lkb1 inactivation. Lkb1 mutation within the developing pancreas caused defective polarity, abnormal cytoskeletal organization, loss of tight junctions and inactivation of AMPK/MARK/SAD family kinases . This led to acinar cell degeneration and acinar-toductal metaplasia culminating in the development of benign pancreatic serous cystadenomas. Despite the loss of AMPK signaling, these tumors failed to show significant upregulation of the mTOR pathway. Moreover, phosphorylation of MRLC-a candidate regulator of Lkb1-AMPK-mediated control of polarity in Drosophila and mammalian colon cancer cells-was increased rather than decreased in the Lkb1 mutants. These data appear to indicate that Lkb1 regulates pancreatic tumorigenesis, at least in part, through control of acinar polarity, and employing pathways other than AMPK-TSC2-mTOR or AMPK-MRLC signaling. Although AMPK remains a plausible candidate for regulation of pancreatic polarity, the complete loss of activity of MARKs, reduced phosphorylation of one of their canonical substrates, MAP4, and the loss of SAD A/B activity in Lkb1 mutants suggest multiple potential mediators of polarity control downstream of Lkb1 in the pancreatic epithelium. It is notable that inactivation of Lkb1 in the adult pancreas does not produce polarity defects, consistent with a role of Lkb1 in the establishment rather than the maintenance of pancreatic epithelial polarity (Hezel AF and Bardeesy N unpublished data) .
Defects in cell polarity were also noted in Lkb1-deficient prostate neoplasms as reflected by the aberrant localization of the tight junction protein, ZO-1. Unexpectedly, these lesions showed increased, rather than decreased, activation of AMPK as reflected by phospho-AMPK (T172) staining, suggesting that an alternative AMPK kinase activates AMPK in evolving prostate neoplasm (Pearson et al., 2008) . The authors present evidence that both PI3K and b-catenin pathways were upregulated in prostate tumors, both of which could contribute to the polarity alterations observed in the tumors.
In contrast to the polarity defects observed in the previous models, the Lkb1 mutant endometrial tumors have intact polarity despite exhibiting highly invasive behavior (Contreras et al., 2008) . These well-differentiated tumors closely resemble normal glands and have normal apical polarization including the presence of abundant microvilli on the apical cell surface. Although these tumors lose AMPK signaling, as reflected by decreased AMPK active site phosphorylation and decreased phosphorylation of the AMPK substrate acetyl-Coenzyme A carboxylase, mTOR was not deregulated relative to normal tissue as determined by phosphorylation of S6 kinase. mTOR also does not appear to be significantly upregulated in Lkb1 deficient squamous cell carcinomas from DMBA-treated Lkb1 þ /À mice. Furthermore, using Lkb1 null cell lines generated from these tumors, it was shown that Lkb1 reconstitution could induce a senescence-like growth arrest in an AMPK-independent and p53-independent manner . The AMPK-mTOR pathway is deregulated in the mouse K-RAS G12D Lkb1 mutant lung cancer model and in human lung cancer cell lines. Lkb1 overexpression restores AMPK signaling in human lung cancer cell lines and prevents their invasion and metastasis. However, the authors identified the NEDD9 protein-whose expression is repressed in cells overexpressing LKB1-as a key mediator of lung cancer cell invasion, yet blockade of mTOR by rapamycin did not repress NEDD9 expression. Therefore, LKB1 can mediate invasion independently of AMPK-TSC2-mTOR signaling.
Some of the data above appear to point away from repression of mTOR-and in some cases AMPK activation-as being the critical mediators of tumor suppression downstream of LKB1 in some contexts. In contrast, studies using pharmacological activators of AMPK suggest that the AMPK signaling may be an important barrier to tumorigenesis. Specifically, AMPK activators (for example, phenformin or metformin) substantially attenuated tumorigenesis in Pten þ /À mice. These observations indicate that an LKB1-AMPK pathway restrains tumorigenesis in the setting of an active PI3K pathway. Hence, in the presence of at least partial LKB1 function, AMPK activators may be effective in the preventing or attenuating growth of PTEN mutant human tumors. Notably, retrospective studies of diabetics taking metformin have suggested a significant decrease in cancer risk compared to diabetics receiving insulin therapy (Evans et al., 2005) . Metformin administration also prevented pancreatic tumor development in a hamster model (Schneider et al., 2001 ). It will be of interest to determine whether this protective effect of Lkb1-AMPK signaling involves systemic metabolic effects, metabolic effects in evolving tumor cells, maintenance of cell polarity, or a combination of these processes. Recent data suggest that this pharmacological activation of AMPK may also be beneficial for treatment of established tumors with intact Lkb1-AMPK-TSC signaling, as metformin slows proliferation of cancer cell lines (Zakikhani et al., 2006) .
Conclusions
Although the somatic inactivation of Lkb1 in multiple organs leads to neoplasia, a common underlying mechanism of tumor suppression is not yet apparent. Polarity defects appear to be associated with neoplastic change in a number of contexts. Notable in this regard is the observation that the Lkb1-deficient pancreas exhibits polarity defects before the onset of tumorigenesis, indicating such polarity defects may be a primary cause of tumor initiation . However, genetic approaches will be needed to directly identify the critical targets of Lkb1 and the associated cellular processes of transformation. These experiments are complicated by the presence in the mammalian genome of two AMPKa homologs, two SAD kinases, and four MARK homologs as well as six other AMPKrelated kinases that are bona fide LKB1 substrates.
Another complicating factor is that LKB1 could have stage-specific functions in tumorigenesis that are not apparent from studies of tissues or cell lines from advanced stages of disease. For example, it is possible that the early loss of Lkb1 could make cells sensitive to subsequent oncogenic transformation by allowing loss of polarity under oncogenic stress and thereby losing the natural barrier to proliferation and transformation that is provided by appropriate epithelial polarity. In such a case, LKB1 loss may promote tumor initiation but may not contribute a tumor maintenance function (that is, deregulation of LKB1 controlled pathways might not be required for sustained oncogenic growth of some established tumors). Although LKB1 restoration can block proliferation or metastasis of some LKB1 mutant cancer cell lines, the mechanism may be non-physiological and/or involve targets that are not relevant to the role of LKB1 in the natural history of the tumor. The role of LKB1 in cancers is particularly difficult to conceptualize as LKB1 deficiency renders both primary cells and cancer cell lines sensitive to cell death in response to energy stress (Shaw et al., 2004b; Carretero et al., 2007; Memmott et al., 2008) . Therefore it is likely that specific cooperating molecular alterations are required for LKB1-deficient cells to withstand energy stress during tumor progression. Overall, addressing the tumor maintenance role of Lkb1 will be essential in devising therapeutic strategies against LKB1 mutant cancers.
